Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21285727 | 1.00 | EP300 (0.85) | EP300CREBBP | |
| SCHEMBL23242143 | 1.00 | EP300 (0.85) | EP300CREBBP | |
| SCHEMBL30011581 | 1.00 | EP300 (0.85) | EP300CREBBP | |
| SCHEMBL21285895 | 0.92 | EP300 (1.00) | EP300CREBBP | |
| SCHEMBL21286335 | 0.92 | EP300 (1.00) | EP300CREBBP | |
| SCHEMBL23242099 | 0.92 | EP300 (1.00) | EP300CREBBP | |
| SCHEMBL30011000 | 0.92 | EP300 (1.00) | EP300CREBBP | |
| SCHEMBL23242128 | 0.91 | EP300 (0.88) | EP300CREBBP | |
| SCHEMBL21285725 | 0.91 | EP300 (0.88) | EP300CREBBP | |
| SCHEMBL21285729 | 0.91 | EP300 (0.88) | EP300CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3752497-B1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| US-20210115008-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS, INC. | 2021-04-22 | — | — | US | disclosed |
| US-20210115008-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS, INC. | 2021-04-22 | — | — | US | disclosed |
| WO-2021021893-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| WO-2019161162-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2019-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115008-A1 | P300/CBP HAT INHIBITORS | EP300, HDAC1, KAT2A | EP300 1/4885CREBBP 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.